Welcome to our dedicated page for Psyence Biomedical Ltd. SEC filings (Ticker: PBM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Psyence Biomedical Ltd. (PBM) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a foreign private issuer listed on the Nasdaq Capital Market. Psyence BioMed files under Form 20-F and furnishes interim and event-driven information on Form 6-K, as reflected in the available filings.
Through these filings, investors can review unaudited interim condensed consolidated financial statements and accompanying Management’s Discussion and Analysis for specified periods, as referenced in a Form 6-K describing financial statements for the three and six months ended September 30 in certain years. Exhibits to Form 6-K reports may also include press releases, equity incentive plan documents, and details of material agreements.
Some PBM filings describe corporate and governance developments, such as changes in executive roles, appointments to the Board of Directors, and amendments to capital arrangements. For example, a Form 6-K outlines the appointment of the company’s Chief Financial Officer to the Board and the entry into an amendment to a Common Stock Purchase Agreement with an investor, providing context on the company’s access to capital.
Other Form 6-K submissions incorporate press releases on topics such as clinical trial progress, strategic investments in PsyLabs, and share-related actions. These filings may be incorporated by reference into the company’s shelf registration statements on Form F-3, as indicated in the text of certain reports.
On Stock Titan, PBM filings are updated as new documents are posted to the SEC’s EDGAR system. AI-powered summaries can help explain key elements of lengthy filings, highlight changes in capital structure, and clarify the implications of agreements or governance updates. Users can quickly scan for items such as interim financial results, capital management disclosures, and material contracts, and can also monitor how press releases referenced in filings align with the company’s broader clinical and strategic narrative.
Psyence Biomedical (Nasdaq: PBM) filed its FY-2025 Form 20-F covering the year ended March 31 2025.
Key disclosures include:
- 568,021 common shares outstanding at year-end
- Securities trade as PBM (shares) and PBMWW (warrants) on Nasdaq
- Reports under IFRS; classified as a non-accelerated filer and emerging growth company
- Not a well-known seasoned issuer; no SOX 404(b) auditor attestation
- Company has no products yet approved for commercial sale and depends on successful clinical trials and regulatory clearance
- Forward-looking statements flag risks around Nasdaq listing stability, share price volatility, talent retention, supply chain, IP licensing and macro conditions
The filing provides full audited financials, risk factors and corporate-governance disclosures but does not announce new financings, M&A or product approvals.